Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9856479 | 0.86 | ALDH1A1 (0.34) | ALDH1A1MEN1ABCB11GSRTSHR | |
| SCHEMBL2347991 | 0.79 | CA12 (0.32) | ALDH1A1MEN1ABCB11GSRTSHR | |
| SCHEMBL8048766 | 0.78 | PPARD (0.38) | MEN1TSHRKMT2A | |
| SCHEMBL22616909 | 0.71 | LMNA (0.37) | ALDH1A1MEN1TSHRHTTKMT2A | |
| SCHEMBL11121024 | 0.70 | ALDH1A1 (0.38) | ALDH1A1MEN1ABCB11GSRTSHR | |
| SCHEMBL21327727 | 0.70 | ADRA2A (0.46) | ALDH1A1MEN1ABCB11GSRTSHR | |
| SCHEMBL28571071 | 0.70 | ALDH1A1 (0.59) | ALDH1A1MEN1ABCB11GSRTSHR | |
| SCHEMBL9435841 | 0.70 | LMNA (0.33) | ALDH1A1MEN1ABCB11GSRTSHR | |
| SCHEMBL188597 | 0.67 | — | — | |
| SCHEMBL995987 | 0.64 | TSHR (0.37) | ALDH1A1MEN1ABCB11GSRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4213903-A1 | SYSTEM AND METHOD FOR INTEGRATED BLOOD VESSEL EMBOLIZATION AND LOCALIZED DRUG DELIVERY | Farha, Said (US) | 2023-07-26 | — | — | EP | claimed |
| US-11369570-B2 | Aptamer bioconjugate drug delivery device | GREENMARK BIOMEDICAL INC. (US) | 2022-06-28 | — | — | US | claimed |
| US-20210338585-A1 | APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE | GREENMARK BIOMEDICAL INC. | 2021-11-04 | — | — | US | claimed |
| EP-2645991-B1 | APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE | GREENMARK BIOMEDICAL INC (US) | 2020-02-12 | — | — | EP | claimed |
| WO-2019173446-A1 | POLYAMINE PRODRUGS AND POLYAMINE PRODRUG FORMULATIONS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2019-09-12 | — | — | WO | claimed |
| US-10285943-B2 | Aptamer bioconjugate drug delivery device | GREENMARK BIOMEDICAL INC. (US) | 2019-05-14 | — | — | US | claimed |
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | claimed |
| EP-3027705-A1 | CONFORMANCE CONTROL IN ENHANCED OIL RECOVERY | Maersk Olie & Gas A/S (DK) | 2016-06-08 | — | — | EP | claimed |
| EP-2908809-A2 | METHODS FOR THE EFFECTIVE TREATMENT OF METASTATIC CANCER | Glazier, Arnold (US) | 2015-08-26 | — | — | EP | claimed |
| WO-2015014939-A1 | CONFORMANCE CONTROL IN ENHANCED OIL RECOVERY | MAERSK OLIE OG GAS A/S (DK) | 2015-02-05 | — | — | WO | claimed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1480655-A2 | DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY COMBINATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-12-01 | — | — | EP | claimed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | claimed |
| WO-2003074060-A2 | DNA DEMETHYLASE ANTISENSE AND CHEMOTHERAPY COMBINATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-09-12 | — | — | WO | claimed |
| JP-3193379-B2 | — | — | 2001-07-30 | — | — | JP | claimed |
| EP-0626943-B1 | BISTRIAZENES AS CHEMOTHERAPEUTIC AGENTS | US HEALTH (US) | 2000-01-26 | — | — | EP | claimed |
| US-5808038-A | ANTICARCER AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-09-15 | — | — | US | claimed |
| US-5672593-A | Bistriazenes as chemotherapeutic agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-09-30 | — | — | US | claimed |
| EP-0626943-A1 | BISTRIAZENES AS CHEMOTHERAPEUTIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-12-07 | — | — | EP | claimed |
| WO-1993009089-A1 | BISTRIAZENES AS CHEMOTHERAPEUTIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-05-13 | — | — | WO | claimed |